Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 11
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 11

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderCoya Therapeutics · 49
Strongest available pathCoya Therapeutics · -3.8%
Widest latest marginFlexion Therapeutics · 1.0%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1COYA · Nasdaq

Coya Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2020Houston, Texas$107.0M market cap
View full Companies Radar profile
49Cautious
Snapshot price$4.56as of page date
Monthly-close return-3.8%since December 2022
FY2025 revenue$0.01BCoya Therapeutics, Inc.
Net margin-267.1%FY2025
P/E snapshot-2.4xone ratio, not a verdict
Prism attention14.0%share across these five
Filing track recordRevenue, USD billions
+32.4%
$0$0.0B$0.0B$0.0BFY2023: $0.006BFY2024: $0.004BFY2025: $0.008B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.1%
52-week position21% through range
$3.71$7.75
News mentions541
Community mentions0partial coverage
U.S.-scope patents27
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal87/100
Innovation pulse8/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2KPTI · Nasdaq

Karyopharm

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Natick, Massachusetts$46.7M market cap
View full Companies Radar profile
49Cautious
Snapshot price$2.06as of page date
Monthly-close return-97.6%five-year window
FY2025 revenue$0.15BKaryopharm Therapeutics Inc.
Net margin-134.2%FY2025
P/E snapshot-0.7xone ratio, not a verdict
Prism attention33.9%share across these five
Filing track recordRevenue, USD billions
-30.4%
$0$0.1B$0.1B$0.2BFY2021: $0.210BFY2022: $0.157BFY2023: $0.146BFY2024: $0.145BFY2025: $0.146B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.7%
52-week position3% through range
$1.79$10.99
News mentions1.3K
Community mentions22partial coverage
U.S.-scope patents368
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal62/100
Management stability90/100
Market position3/100
Capital-event signal60/100
Innovation pulse14/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 16 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PHAT · Nasdaq

Phathom Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2019Menlo Park, California$774.2M market cap
View full Companies Radar profile
49Cautious
Snapshot price$9.57as of page date
Monthly-close return-70.2%five-year window
FY2025 revenue$0.17BPhathom Pharmaceuticals, Inc.
Net margin-126.3%FY2025
P/E snapshot8.6xone ratio, not a verdict
Prism attention16.8%share across these five
Filing track recordRevenue, USD billions
+25576.0%
$0$0.1B$0.1B$0.2BFY2023: $0.001BFY2024: $0.055BFY2025: $0.175B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1502.4%
52-week position13% through range
$8.21$18.31
News mentions651
Community mentions14partial coverage
U.S.-scope patents1
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal81/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4XBIO · Nasdaq

Xenetic

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1997Cambridge, Massachusetts$9.8M market cap
View full Companies Radar profile
49Cautious
Snapshot price$4.19as of page date
Monthly-close return-79.6%five-year window
FY2025 revenue$0.00BXenetic Biosciences, Inc.
Net margin-90.1%FY2025
Prism attention8.6%share across these five
Filing track recordRevenue, USD billions
+156.4%
$0$0.0B$0.0B$0.0BFY2021: $0.001BFY2022: $0.002BFY2023: $0.003BFY2024: $0.003BFY2025: $0.003B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 26.5%
52-week position19% through range
$1.90$13.93
News mentions333
Community mentions0partial coverage
U.S.-scope patents14
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5PCRX · Nasdaq

Flexion Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005Redwood City, California$1.02B market cap
View full Companies Radar profile
48Cautious
Snapshot price$25.90as of page date
Monthly-close return-53.8%five-year window
FY2025 revenue$0.73BPacira BioSciences, Inc.
Net margin1.0%FY2025
P/E snapshot74.0xone ratio, not a verdict
Prism attention26.7%share across these five
Filing track recordRevenue, USD billions
+70.3%
$0$0.2B$0.5B$0.7BFY2020: $0.427BFY2021: $0.539BFY2022: $0.667BFY2023: $0.675BFY2025: $0.726B20202021202220232025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 14.2%
52-week position80% through range
$18.80$27.66
News mentions1.0K
Community mentions10partial coverage
U.S.-scope patents68
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal58/100
Management stability90/100
Market position8/100
Capital-event signal65/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Coya Therapeutics
-3.8%
Flexion Therapeutics
-53.8%
Phathom Pharmaceuticals
-70.2%
Xenetic
-79.6%
Karyopharm
-97.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Flexion Therapeutics
$0.73B
Phathom Pharmaceuticals
$0.17B
Karyopharm
$0.15B
Coya Therapeutics
$0.01B
Xenetic
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Flexion Therapeutics
1.0%
Xenetic
-90.1%
Phathom Pharmaceuticals
-126.3%
Karyopharm
-134.2%
Coya Therapeutics
-267.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Karyopharm
33.9%
Flexion Therapeutics
26.7%
Phathom Pharmaceuticals
16.8%
Coya Therapeutics
14.0%
Xenetic
8.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Karyopharm leads the conversation

It holds 33.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.15B.

Price path

Coya Therapeutics leads the available price paths

Its monthly-close return is -3.8% for the since December 2022. At the other end, Karyopharm is -97.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Flexion Therapeutics has the widest latest margin

Its FY2025 net margin is 1.0%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Coya Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -2.4x while its since December 2022 price return is -3.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KPTI

Karyopharm

1,313available Prism news records

Prism top themes

Legal, arbitration & regulatory
21
Capital allocation & transactions
16
Price action & investor response
12
Leadership & governance
11
Earnings & financial performance
7

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-0.5%182 latest 12m vs 183 prior 12m
2024-01: 4 mentions2024-02: 15 mentions2024-03: 8 mentions2024-04: 7 mentions2024-05: 12 mentions2024-06: 7 mentions2024-07: 5 mentions2024-08: 8 mentions2024-09: 5 mentions2024-10: 6 mentions2024-11: 15 mentions2024-12: 2 mentions2025-01: 11 mentions2025-02: 83 mentions2025-03: 19 mentions2025-04: 8 mentions2025-05: 11 mentions2025-06: 10 mentions2025-07: 6 mentions2025-08: 11 mentions2025-09: 8 mentions2025-10: 14 mentions2025-11: 9 mentions2025-12: 16 mentions2026-01: 9 mentions2026-02: 22 mentions2026-03: 36 mentions2026-04: 12 mentions2026-05: 26 mentions2026-06: 13 mentions2024-012026-06

Machine-classified coverage tone

92.9% positive-2.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 16checkpoint inhibitors lymphoma 7phase iii trial 6immunomodulatory drugs 5car-t myeloma 5stem cell transplant myeloma 5cancer biomarkers 4phase ii trial 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-06-08–2026-06-12 · trend and themes shown through 2026-06
Areas of research · PCRX

Flexion Therapeutics

1,034available Prism news records

Prism top themes

Leadership & governance
32
Capital allocation & transactions
25
Price action & investor response
25
Earnings & financial performance
22
Legal, arbitration & regulatory
17

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-34.8%137 latest 12m vs 210 prior 12m
2024-01: 10 mentions2024-02: 10 mentions2024-03: 8 mentions2024-04: 4 mentions2024-05: 12 mentions2024-06: 1 mentions2024-07: 9 mentions2024-08: 5 mentions2024-09: 6 mentions2024-10: 11 mentions2024-11: 9 mentions2024-12: 4 mentions2025-01: 43 mentions2025-02: 54 mentions2025-03: 31 mentions2025-04: 20 mentions2025-05: 6 mentions2025-06: 12 mentions2025-07: 5 mentions2025-08: 5 mentions2025-09: 3 mentions2025-10: 7 mentions2025-11: 7 mentions2025-12: 12 mentions2026-01: 16 mentions2026-02: 12 mentions2026-03: 14 mentions2026-04: 28 mentions2026-05: 25 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

92.7% positive+19.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

patent litigation 24composition patents 11investment deal 8shareholder vote 6angel investors 6company valuation 5earnings report 5stock price 5

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-29–2026-06-13 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

COYA

Coya Therapeutics

through 2026-04-02
Leadership changes 12Business contracts 3Listing / IPO 2Company announcements 1
  1. Leadership changes

    Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024.

  2. Listing / IPO

    Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it has priced an underwritten public offering of 3,636,364 shares of its common stock at a public offering price of $5.50 per share of common stock.

  3. Company announcements

    Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KPTI

Karyopharm

through 2026-04-21
Company announcements 37Earnings releases 20Leadership changes 1Listing / IPO 1
  1. Company announcements

    Karyopharm Therapeutics Inc. (NASDAQ: KPTI) said its Phase 3 SENTRY trial in frontline myelofibrosis has been selected for a late-breaking oral presentation at the 2026 American Society of Clinical Oncology annual meeting, giving the small-cap oncology company a larger scientific stage just weeks after reporting topline data.

  2. Earnings releases

    Total revenue for the fourth quarter of 2025 was $34.1 million, compared to $30.5 million for the fourth quarter of 2024. Net loss was $102.2 million.

  3. Listing / IPO

    Karyopharm Therapeutics Inc. is seeking to raise up to $80 million from a proposed IPO.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PHAT

Phathom Pharmaceuticals

through 2026-05-03
Earnings releases 18Company announcements 3Leadership changes 3Board updates 1Regulatory 1
  1. Earnings releases

    Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized continued progress in deepening adoption of its acid-suppression medicine VOQUEZNA among gastroenterologists.

  2. Leadership changes

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer.

  3. Regulatory

    A key upcoming event is the FDA’s decision on the Citizens’ Petition, expected in early June, which is seen as a significant catalyst for the stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

XBIO

Xenetic

through 2025-11-14
Earnings releases 3Leadership changes 2
  1. Earnings releases

    Revenue for the three months ended September 30, 2025 increased by approximately $0.4 million, or 67.2%, to approximately $1.0 million from approximately $0.6 million for the three months ended September 30, 2024.

  2. Leadership changes

    Xenetic Biosciences plc, of Lexington, Mass., added Roger D. Kornberg to its board.

  3. Earnings releases

    Net loss for the quarter ended September 30, 2025 was approximately $0.5 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PCRX

Flexion Therapeutics

through 2025-02-14
Earnings releases 2Listing / IPO 1
  1. Listing / IPO

    Flexion Therapeutics Inc. priced its IPO of 5 million shares of common stock at $13 each.

  2. Earnings releases

    Flexion Therapeutics Inc., of Burlington, Mass., reported its net sales of pain drug for osteoarthritis of the knee Zilretta were $9.5 million for fourth quarter and $22.5 million for the full year.

  3. Earnings releases

    Flexion Therapeutics Inc., of Burlington, Mass., reported net sales of non-opioid pain drug Zilretta (triamcinolone acetonide extended-release injectable suspension) totaling $7 million for the third quarter, up 84 percent over the second quarter. The company's net loss for the quarter was $43.6 million, or $1.15 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 51–58. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Flexion Therapeutics and Flexion Therapeutics

Flexion Therapeutics has the largest displayed latest revenue at $0.73B; Flexion Therapeutics has the widest displayed latest margin at 1.0%.

Open Flexion Therapeutics in Companies Radar
Comparisons
Anomalies

Flexion Therapeutics has the widest attention-readiness rank gap

It ranks #2 by measured news attention (26.7%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Flexion Therapeutics in Companies Radar

Phathom Pharmaceuticals shows a price-operating divergence to inspect

Its displayed filing-revenue change is +25576.0% while its available monthly-close return is -70.2%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Phathom Pharmaceuticals in Companies Radar
Explanations

Attention measures coverage volume, not quality

Karyopharm's 33.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Karyopharm in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Coya Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open Coya Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon